You are here

Development of a Novel Whole Genome Sequencing-based Platform for Rapid Identification and Antimicrobial Profiling of Uropathogens

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI167193-01
Agency Tracking Number: R43AI167193
Amount: $303,932.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: R
Solicitation Number: PA20-260
Solicitation Year: 2020
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-06-01
Award End Date (Contract End Date): 2022-09-30
Small Business Information
Brookline, MA 02445-7105
United States
DUNS: 080319311
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (857) 249-2417
Business Contact
Phone: (857) 249-2417
Research Institution

Complicated urinary tract infections are severe or life-threatening infections that extend beyond a simple bladder
infection and occur most frequently in hospitalized patients. There are over 2.8 million cases of complicated
urinary tract infections in the U.S. each year, with 20% of cases progressing to urosepsis, leading to nearly
150,000 deaths each year. Effective management of complicated urinary tract infections requires the rapid
identification of the causative bacterial pathogen(s) and the associated antibiotic resistance profile. The current
standard of care, however, is urine culture, which requires 2-3 days from specimen collection until actionable
information to guide patient treatment is generated. Hence, there is an urgent need for diagnostic tools that will
allow for the rapid identification of uropathogens and their antimicrobial resistance/sensitivity profile(s). To
address this unmet need, Day Zero Diagnostics (DZD) is developing a diagnostic workflow that leverages whole
genome sequencing and machine learning to deliver high resolution species identification and antimicrobial
resistance and susceptibility profiling from a patient sample without the need for urine culture. These data will
guide evidence-based treatment decisions to improve patient care. The aims of this proposal are to (1)
demonstrate ultra-high enrichment of bacterial DNA from a diverse range of species from urine samples and (2)
optimize a sample preparation pipeline to deliver an actionable result in six hours or less, a clinically relevant
timeframe for complicated urinary tract infection. The proposed Specific Aims, with quantifiable target metrics,
are designed to demonstrate proof-of-concept in advance of the development of a commercial in vitro diagnostic.
Upon Phase I completion, Phase II will focus on optimizing the workflow, expanding test capabilities, and
analytical and clinical validation studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government